Prognostic Significance of CD109 Expression in Patients with Ovarian Epithelial Cancer

• Published in: Journal of pathology and translational medicine Vol. 53; no. 4; pp. 244 - 252
• Main Authors: Kim, So Young, Choi, Kyung Un, Hwang, Chungsu, Lee, Hyung Jung, Lee, Jung Hee, Shin, Dong Hoon, Kim, Jee Yeon, Sol, Mee Young, Kim, Jae Ho, Kim, Ki Hyung, Suh, Dong Soo, Kwon, Byung Su
• Format: Journal Article
• Language: English
• Published: Korea (South) The Korean Society of Pathologists and the Korean Society for Cytopathology 01.07.2019; Korean Society of Pathologists & the Korean Society for Cytopathology; 대한병리학회
• Subjects: CD109; Original; Ovarian epithelial carcinoma; Prognosis; 병리학; Ovarian epithelial carcinoma; CD109; Prognosis
• ISSN: 2383-7837; 2383-7845
• DOI: 10.4132/jptm.2019.04.16

Ovarian epithelial cancer (OEC) is the second-most common gynecologic malignancy. CD109 expression is elevated in human tumor cell lines and carcinomas. A previous study showed that CD109 expression is elevated in human tumor cell lines and CD109 plays a role in cancer progression. Therefore, this study aimed to determine whether CD109 is expressed in OEC and can be useful in predicting the prognosis. Immunohistochemical staining for CD109 and reverse transcription-quantitative polymerase chain reaction was performed. Then we compared CD109 expression and chemoresistance, overall survival, and recurrence-free survival of OEC patients. Chemoresistance was evaluated by dividing into good-response group and poor-response group by the time to recurrence after chemotherapy. CD109 expression was associated with overall survival (p = .020), but not recurrence-free survival (p = .290). CD109 expression was not an independent risk factor for overall survival due to its reliability (hazard ratio, 1.58; p = .160; 95% confidence interval, 0.82 to 3.05), although we found that CD109 positivity was related to chemoresistance. The poor-response group showed higher rates of CD109 expression than the good-response group (93.8% vs 66.7%, p = .047). Also, the CD109 mRNA expression level was 2.88 times higher in the poor-response group as compared to the good-response group (p = .001). Examining the CD109 expression in patients with OEC may be helpful in predicting survival and chemotherapeutic effect.